Skip to main navigation Skip to search Skip to main content

CNP-103-CL-201: A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes

Project: Research

Project Details

StatusActive
Effective start/end date09/8/25 → 03/2/27

Funding

  • COUR Pharmaceutical Development Company Incorporated: $28,582.20